Researchers report that a drug approved for treating patients with autoimmune disease helped to prevent lung damage and death in mice infected with the SARS-CoV-2 virus, which causes COVID-19 in humans.
Regulating the endothelin system may help inflammatory conditions. Studies found improvements in lupus, colitis and kidney injury mouse models. Findings will be presented virtually at the Seventeenth International Conference on Endothelin, hosted and organized by the American Physiological Society.
University at Buffalo researchers have developed a new treatment that uses reverse vaccination to pre-expose the body to medications and build immune tolerance. The treatment could be applied to a broad range of drug therapies, autoimmune disorders and allergies.
To mark its 30-year legacy and global impact on the autoimmune community, today, the American Autoimmune Related Diseases Association (AARDA) is pleased to announce its new name: the Autoimmune Association.
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
Researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, deliver a biologic drug in response to inflammation.
Two National Institute of Health (NIH) grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences, is the Principal Investigator on both grants — $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.
A Michigan Medicine physician will co-lead a NIH study of antibody response to an additional dose of the COVID-19 vaccine in people with autoimmune disease. The trial will also assess whether pausing immunosuppressive medication improves immune response to the booster shot.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
The absence of a protein that activates the body’s antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition that is treatable with an FDA-approved class of drugs known as TNF (tumor necrosis factor) inhibitors, a global research team led by Mount Sinai has found.
The FDA and CDC have just approved and recommended an additional dose of mRNA COVID-19 vaccines for moderately and severely immunocompromised people. Who should get it?
CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries. Eligible rheumatology registry patients will contribute biological specimens that will be linked to longitudinal provider reported clinical and patient reported outcomes.
How effective COVID-19 vaccines have been in immunosuppressed and rheumatic disease patients remains an incompletely answered question. The American College of Rheumatology (ACR) has organized an expert panel to share what we are learning from real-world data and answer questions.
The US Food and Drug Administration approved the drug anifrolumab (Saphnelo) on August 2, 2021 for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
Regulatory T cells (Tregs) help control inflammation and autoimmunity in the body. Unfortunately, it has proven difficult to find the right molecular ingredients to induce stable iTregs. A new study reports that Vitamin C and TET proteins can work together to give Tregs their life-saving power.
In a new University of California, Irvine-led study, researchers found that a certain protein prevented regulatory T cells (Tregs) from effectively doing their job in controlling the damaging effects of inflammation in a model of multiple sclerosis (MS), a devastating autoimmune disease of the nervous system.
Diagnosing a rare medical condition is difficult. Identifying a treatment for it can take years of trial and error. In a serendipitous intersection of research expertise, an ill patient in this case a child and innovative technology, Bachmann-Bupp Syndrome has gone from a list of symptoms to a successful treatment in just 16 months.
Researchers at Michigan Medicine have discovered another functional autoantibody in COVID-19 patients that contributes to the disease’s development and the “firestorm” of blood clots and inflammation it induces. The autoantibody makes it harder for the body to degrade neutrophil extracellular traps, the toxic webs of DNA and proteins produced by overactive immune cells at heightened levels in COVID patients.
Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not. In a study published in Neurology, Mayo Clinic researchers and colleagues assessed if inflammation leads to permanent scarring in these three diseases:
Nanofiber-based treatments stimulate the body to mount its own biological attack on immune disorders.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right